Equities research analysts at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a report issued on Thursday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
The firm has a market cap of $3.00 million, a P/E ratio of 0.00 and a beta of 1.13. Navidea Biopharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.17. The firm has a 50-day moving average of $0.04 and a two-hundred day moving average of $0.05.
About Navidea Biopharmaceuticals
Featured Articles
- Five stocks we like better than Navidea Biopharmaceuticals
- What is the Shanghai Stock Exchange Composite Index?
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- CD Calculator: Certificate of Deposit Calculator
- These 2 Retail Traders Favorites are Nearing Major Breakouts
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Snowflake is Melting… Up, With a Double-Digit Upside Potential
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.